3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
2
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphangioleiomyomatosis
1
Liver Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Chemoprevention
1
Carcinoma, Hepatocellular
1
Interventions
Irinotecan
31
Paclitaxel
27
Gemcitabine
27
Cisplatin
25
Docetaxel
20
Oxaliplatin
16
Fluorouracil
15
alvocidib
13
Leucovorin
13
Carboplatin
13
Capecitabine
12
Bortezomib
10
Early Intervention, Educational
9
Topotecan
8
Taxes
8
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
7
ixabepilone
6
Vorinostat
6
Temozolomide
6
Sorafenib
6
Immunohistochemistry
6
Immunoenzyme Techniques
6
Bevacizumab
6
7-hydroxystaurosporine
6
tanespimycin
5
Pharmacogenomic Testing
5
Pemetrexed
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Etoposide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Unspecified Adult Solid Tumor, Protocol Specific
×
Resveratrol
×
Clear all
NCT00098969
2012-12-17
IRB 2004-535
National Cancer Institute (NCI)
Phase 1
Completed
40 enrolled